Seca launches first portable body composition scan for primary care

The latest stories trending on MedCity News.

Editor's Pick

Top Story Seca Launches First Portable Body Composition Scan for Primary Care German medical device company seca released the first portable body composition scanner designed for primary care. The scanner seeks to give primary care providers a more accurate picture of their patient's health, as well as help them spot certain conditions — such as sarcopenia, obesity and metabolic disorders — earlier. Sponsored The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond Presented by Fondren Orthopedic Group Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry. Learn More Only 3 Weeks Away! MedCity News' flagship event for the entire healthcare innovation ecosystem! Join us May 20-21 in Chicago for two days packed with fresh ideas, strategic insights, and unmatched networking. Register Now

Featured News

Time is Running Out to Join the Healthcare Innovation Conversation at INVEST 2025 MedCity INVEST is a boutique healthcare investor conference scheduled for May 20-21 at the Willis Tower in Chicago. Register today! How Imagine360 Saved this Employer 19% Compared to Traditional Health Plans An analysis by Axene Health Partners revealed that Imagine360 delivered 19% in annual savings—equating to $7.7 million—compared to traditional health plans for Rollins, a pest control company. Debunked Episode 15: How Did UnitedHealth Fail to Anticipate a Rise in Medical Utilization Costs? United Healthcare's shocking quarterly earnings miss, a new regular feature on the Trump administration's healthcare moves, and the future of value-based care. That's the focus of the latest episode of the Debunked podcast with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. FDA Nod for J&J Autoimmune Drug is First of Potentially Many for the Projected Blockbuster Product Johnson & Johnson's Imaavy is now FDA-approved for treating generalized myasthenia gravis, introducing competition to Argenx and UCB drugs that treat this rare neuromuscular disorder. J&J is also developing its new drug for other diseases and projects it could reach $5 billion in peak sales across multiple rare and prevalent conditions. Expanding Support for Mail-Based Naloxone Delivery The opioid settlement funds provide a crucial opportunity to get increased state or municipal funding behind mail-based naloxone delivery. Through partnering with existing organizations that already have robust infrastructure in place and substantial experience in mail-based naloxone municipalities can scale efforts efficiently.

Video   What Should Employers Be Thinking About as They Develop Their Pharmacy Benefit Strategy? For Josh Golden, Capital Rx's senior vice president of strategy, it boils down to one question employers need to be asking themselves: Does my pharmacy benefit manager make more money when I spend more money? Most PBM profit models are tied directly to the price and volume of drugs, he noted.

Sponsored The Top 6 Best Analytics Tools for Health Care Revenue in 2025 Presented by Millennia Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources. Learn More

Resources

MedCity Pivot: What if Pancreatic Cancer Became a Chronic Disease? Ben Zeskind, co-founder, president and CEO of Immuneering, is attempting a new approach to treat certain types of cancers. If it works, there will be a vast improvement in the quality of life of cancer patients. Listen now

MedCity News • PO Box 901 • New York, NY unsubscribe